Hormonal
Tirzepatide produces significant weight loss (mean 18.73%) and improves quality of life in overweight or obese adults without diabetes, but significantly increases the risk of adverse events compared to placebo.
Tirzepatide is a highly effective treatment for weight loss in non-diabetic overweight or obese adults, producing an average 18.73% body weight loss. However, it comes with a significantly higher risk of adverse events, particularly gastrointestinal issues, compared to placebo. Patients should be monitored closely for these side effects.
Tirzepatide caused weight loss of 18.73% (95% CI: -21.31 to -16.15) versus placebo... However, tirzepatide had significantly increase in adverse events than placebo (RR: 1.53, 95% CI: 1.18 to 1.98).
Why this rating
Meta-analysis of 3 RCTs with 3901 participants, no risk of bias observed, but limited number of studies.
Source
Efficacy and safety of tirzepatide in overweight or obese adults without diabetes: systematic review and meta-analysis of randomized controlled trials
Ligang Liu et al. · Research Square · 2024
DOI 10.21203/rs.3.rs-4184273/v1
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →